Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 14, 2018 - The FDA announced the approval of Janssen Biotech’s Erleada (apalutamide), for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).
Download PDF
Return to publications
